Right now MOMO is number 15 for the largest percentage gain

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Graph Intelligence: The Winning Edge You know, the financial crime scene ain't what it used to be. Gone are the days when a simple audit trail was enough to sniff out dirty money. Companies like Linkurious are pushing the envelope with graph-powered decision intelligence, and in 2026, they got the nod from Chartis Research as a Category Leader for AML Transaction...

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Elbit Systems Secures Major Asia-Pacific Deal You know, it's not every day that a defense contractor like Elbit Systems (NASDAQ:ESLT) bags a $200 million deal in the Asia-Pacific region. A big move in a high-stakes game where technology, strategy, and geography collide. This isn't some random supply deal; this involves the cutting edge of defense tech—ISTAR and training...

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

PharmAla Biotech Advances MDMA Research with Harvard Trial PharmAla Biotech Holdings Inc has made headlines by agreeing to supply its innovative LaNeo MDMA for an upcoming clinical trial at Harvard's Maclean Hospital. Known for its commitment to neuroscience and psychiatric research, this renowned institution is set to benefit from PharmAla's advanced MDMA formulation....

Changing of the Guard at Socket Mobile Here's a shakeup for you: David A. Holmes just slid into the top slot as President and CEO over at Socket Mobile, Inc. (NASDAQ: SCKT), taking the wheel from Kevin Mills. Mills had been at the helm since the dawn of the millennium—March 2000, to be precise—but come June 12, he's passed the torch to Holmes. That's no small torch...

The Growth Journey of United Airlines Holdings Investing in stocks can be a thrilling journey, especially when considering long-term gains. United Airlines Holdings (NASDAQ: UAL) has shown remarkable performance over the past 15 years, outpacing market averages by an annualized rate of 2.7%. This impressive trajectory has resulted in an average annual return of 14.28%....

Optimism in the U.S. Labor Market: A New Wave of Hiring ZipRecruiter, a notable name in the online employment marketplace, released insights from its recent survey that showcases a revitalized optimism among U.S. employers regarding the labor market. According to the findings, a significant 76% of surveyed employers are gearing up to expand their workforce in the upcoming...

Wave Life Sciences Reports Q3 Financial Results Wave Life Sciences Ltd (NASDAQ: WVE) recently revealed its third-quarter financial results, which unfortunately fell short of analyst expectations. The company announced a loss of 32 cents per share, surpassing the consensus estimate, which predicted a loss of 30 cents per share. Additionally, Wave Life Sciences reported...